Wir sind mit live! Mehr erfahren

Nice

NICE

Börsenwert 6,57 Mrd. $

112,17 USD

-2,74

2,38 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

Vor Börsenbeginn

Nachbörslich

112,17

0,00

0 %

1 Tag

-2,38 %

5 Tage

-5,94 %

1 Monat

6,39 %

3 Monate

11,14 %

6 Monate

6,79 %

Seit Jahresbeginn

0,21 %

1 Jahr

-12,6 %

5 Jahre

-59,37 %

10 Jahre

68,02 %

Profil: Nice is an enterprise software company that serves the customer engagement and financial crime and compliance markets. Software is deployed primarily on the cloud, but also on premises. Within customer engagement, Nice's CXone is the leading CCaaS platform providing solutions such as call routing, interactive voice response, digital self-service, and workforce engagement management. Within financial crime and compliance, Nice offers risk and investigation management, fraud prevention, anti-money-laundering, and compliance solutions.

Mitarbeiter: 9.626

Technologie Software – Anwendung

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 45 %

Neutral 52,5 %

Negativ 2,5 %

Zacks Investment Research

Nice (NICE) Declines More Than Market: Some Information for Investors

Nice (NICE) reached $115.02 at the closing of the latest trading day, reflecting a -2.1% change compared to its last close.

Nice (NICE) Declines More Than Market: Some Information for Investors

The Motley Fool

NICE Stock Analysis: Buy or Sell?

Investors are curious if this is a value stock or a value trap.

NICE Stock Analysis: Buy or Sell?

Zacks Investment Research

Here is What to Know Beyond Why Nice (NICE) is a Trending Stock

Zacks.com users have recently been watching Nice (NICE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Here is What to Know Beyond Why Nice (NICE) is a Trending Stock

Zacks Investment Research

Should You Invest in Nice (NICE) Based on Bullish Wall Street Views?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

Should You Invest in Nice (NICE) Based on Bullish Wall Street Views?

NiCE Names Carahsoft Distributor of the Year for 2025

Company Recognized for Connecting Public Sector Organizations With AI-Powered Customer Service Solutions Company Recognized for Connecting Public Sector Organizations With AI-Powered Customer Service Solutions

NiCE Names Carahsoft Distributor of the Year for 2025

Zacks Investment Research

Nice (NICE) Stock Declines While Market Improves: Some Information for Investors

In the closing of the recent trading day, Nice (NICE) stood at $113.81, denoting a -2.3% move from the preceding trading day.

Nice (NICE) Stock Declines While Market Improves: Some Information for Investors

NiCE Named a Leader in the IDC MarketScape for Worldwide Agentic Contact Center-as-a-Service Platforms

HOBOKEN, N.J.--(BUSINESS WIRE)--NiCE (Nasdaq: NICE) today announced it has been positioned in the Leaders category in the IDC MarketScape: Worldwide Agentic Contact Center–as-a-Service Platforms 2026 Vendor Assessment (doc #US54117326, August 2026). We believe NiCE's position underscores the strength of its unified CX AI platform, bringing CXone and NiCE Cognigy together to orchestrate every interaction across AI agents, human agents and enterprise workflows. This unified approach enables organ.

NiCE Named a Leader in the IDC MarketScape for Worldwide Agentic Contact Center-as-a-Service Platforms

NICE issues final draft guidance recommending ▼ Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales

CAMBRIDGE, England--(BUSINESS WIRE)--FOR UK HEALTHCARE/TRADE MEDIA ONLY Sobi® UK today announced that the National Institute for Health and Care Excellence (NICE) has issued final draft guidance which recommends Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales, only if response to diet and conventional triglyceride-lowering treatments (such as statins and fibrates) has been inadequate. FCS is an ultra-rare.

NICE issues final draft guidance recommending ▼ Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales

NICE: Growth Numbers Look Ugly, But The Setup Is Improving

NICE Ltd. remains a Buy, with AI-driven growth and a low valuation underpinning the investment thesis. AI and Self-Service ARR surged 52% year-over-year, now 15% of cloud revenue, signaling robust demand and platform relevance. Margin compression persists as NICE invests in AI and expansion, but strong cash flow and buybacks provide downside protection.

NICE: Growth Numbers Look Ugly, But The Setup Is Improving

This Nice Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

This Nice Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt